GH Research (NASDAQ:GHRS) Earns “Buy” Rating from HC Wainwright

GH Research (NASDAQ:GHRS)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 321.05% from the stock’s current price. HC Wainwright also issued estimates for GH Research’s FY2029 earnings at $0.10 EPS.

Separately, Canaccord Genuity Group lowered their price target on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th.

GH Research Stock Up 7.8 %

GHRS stock opened at $9.50 on Monday. The firm has a market cap of $494.29 million, a price-to-earnings ratio of -12.03 and a beta of 0.84. GH Research has a twelve month low of $6.00 and a twelve month high of $14.99. The business’s fifty day simple moving average is $8.41 and its two-hundred day simple moving average is $8.92.

Institutional Investors Weigh In On GH Research

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. boosted its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,686,689 shares of the company’s stock after buying an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).